Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up - Should You Buy?

Key Points

• Ono Pharmaceutical's shares gapped up significantly, opening at $11.82 after closing at $10.35.
• The company reported a net margin of 8.75% and earnings per share of $0.26, which missed analysts' expectations of $0.34.
• Ono Pharmaceutical has a market capitalization of $5.55 billion and low debt-to-equity ratio of 0.13, indicating a stable financial position.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report)'s share price gapped up before the market opened on Wednesday . The stock had previously closed at $10.35, but opened at $11.82. Ono Pharmaceutical shares last traded at $11.82, with a volume of 254 shares traded.

Ono Pharmaceutical Price Performance

The stock has a fifty day moving average of $11.20 and a 200-day moving average of $10.95. The company has a quick ratio of 2.44, a current ratio of 2.99 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of 19.06 and a beta of 0.19.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.34 by ($0.08). The business had revenue of $886.27 million during the quarter, compared to analyst estimates of $827.29 million. Ono Pharmaceutical had a net margin of 8.75% and a return on equity of 5.47%.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.